# Comparison of Periodic In-Person ID Care to Daily Tele-ID Care at a Community Hospital

## **Background**

- Access to ID specialists is absent in most U.S. counties.
- Remote access to ID specialists via telemedicine is a potential alternative to in-person ID care.
- As comparative data is lacking, we compared outcomes between periodic in-person and daily remote ID care.

## Methods

- Physicians performed a retrospective electronic health record (EHR) analysis of 200 patients at a 164-bed community hospital, which historically had access to some in-person ID specialists every third day with limited telephonic follow-up.
- In May of 2020, access to a team of Tele-ID specialists was provided through live audio-visual and e-consults, with telephonic consults after-hours and on weekends.
- Outcomes for 100 consecutive patients cared for in-person from 01/2019 to 11/2019 were compared to the first 100 patients cared for via Tele-ID from 05/2020 to 08/2020.



#### **Acknowledgements / References / Disclosures**

Sowmya Nanjappa, Peter Volpe, Nupur Gupta, Sui Kwong Li & Christian Perez have no disclosures. Rima Abdel-Massih is Co-founder, CMO, and share option holder of Infectious Disease Connect. John Mellors is Co-founder, Advisory Board chair, and share option holder of Infectious Disease Connect.

Sowmya Nanjappa, M.D.<sup>1,2</sup>; Peter Volpe, M.D.<sup>1,2</sup>; Nupur Gupta, DO MPH<sup>1,2</sup>; Sui Kwong Li, M.D.<sup>1,2</sup>; Christian Perez, M.D.<sup>1,2</sup>; Kate Gass, BSN<sup>1</sup>; John W. Mellors, M.D.<sup>1,2</sup>; Rima C. Abdel-Massih, M.D.<sup>1,2</sup> Contact: nanjappas@upmc.edu

1. Division of Infectious Diseases, UPMC 2. Infectious Disease Connect, Pittsburgh PA USA





## **Conclusions**

Based upon the findings of this study, remote Tele-ID care is a viable solution where access to ID expertise is limited.

- A Tele-ID service with daily availability increased appropriate utilization of ID care at a 150+-bed community hospital.
- Despite higher Charleston Comorbidity Index (CCI) scores in Tele-ID patients, length of stay (LOS) was shorter and discharge on intravenous (IV) antibiotics was less frequent when compared to In-person service and showed no difference in ID related readmissions or in-house mortality.

### Results

- Of the 100 patients seen via Tele-ID, 73 were live initial consults and 27 initial e-consults. Most patients were Caucasian, male, and >60 years old (**Table 1**).
- These 100 consults occurred over four months compared with 11 months for the 100 in-person ID consults, revealing greater utilization of Tele-ID services. Additionally, Tele-ID patients had: (**Table 2**):
- Significantly higher CCI scores (5.3 vs 4.5, p=0.047)
- Shorter LOS (7.5 vs 9.08 days, p=0.003)
- Less frequent discharges with IV antibiotics (34% vs 51%, p=0.007)
- More frequent discharges on oral antibiotics (39% vs 23%, p=0.014
- No significant differences in the frequency of transfers to tertiary care (13% vs 14%, p=0.84) or in-hospital mortality (2% vs 2%)
- While only one readmission for a patient who received Tele-ID care was ID-related (a new *C.difficile infection*), the 30-day readmission rate was higher for Tele-ID (11% vs 1%, p<0.01).
- The diversity of ID diagnoses made under Tele-ID and in-person care was not different (**Figure 1**).

Figure 1. Diagnoses

Diversity of ID Diagnoses by Service

Bloodstream Infection
SSTI
GU/GYN Infection
Bone and Joint Infection
Other
Respiratory Infection
Non-Infectious
COVID-19
CNS Infection
Tick-borne Illness
Endovascular Infection

0 10 20 30 40 50 60

Number of People

**Table 1.** Patient Demographics

	In-person ID Service	Tele-ID service	p-value
Total Encounters	100	100	
Mean age (years)	63.59	67.84	0.0553
Caucasian (%)	100	98	1.552
Female (%)	41	44	0.668
CCI score (mean)	4.5	5.3	0.047

Table 2. Outcomes

	In-person ID Service	Tele-ID Service	p-value
Average LOS (days)	9.08	7.5	0.003
Discharge on IV antibiotics (%)	51	34	0.007
Discharge on PO antibiotics (%)	23	39	0.014
Transfer to tertiary care center (9	<b>%)</b> 14	13	0.84
In-house mortality (%)	2	2	-
30-Day readmission (%)	1	11	0.007